ASX Stock

At Trader Dealer we understand the importance of information. You can use our handy company information finder to get key fundamental data about any company listed on the ASX.

Simply enter the stock code or the name of the company you are interested in for ASX share price information, company size, research analyst forecast, share and financial ratios, as well as a business and financial summary.

Don’t know the ASX code of the stock you want? Just click on the letter below for a full alphabetical listing.


Enter ASX Stock Code

Bookmark Page !



View all Companies by Letters

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z 


 
 

Cellmid Limited
Industry Group: Biotechnology / Medical Research - Biotechnology

Trade Online with Trader Dealer

Sorry, No Chart Available.

Business Summary
Cellmid Limited is a biotechnology company. It is engaged in developing a range of therapeutic and diagnostic products around midkine. Its disease indications include inflammatory and autoimmune conditions and cancer. Its in-house diagnostic product development programs include (MK) ELISA, CAN104 project, CS5000 and CK3000 projects. As of June 30, 2010, it had completed validation of its midkine (MK) ELISA system in healthy individuals and patients blood samples. It has veterinary cancer diagnostic program with the CAN104 project to assess the value of midkine for the early diagnosis of the most common cancer types in dogs, including mammary carcinoma, hemangiosarcoma, osteosarcoma and specified skin tumours, mast cell tumours, melanomas and squamous cell carcinomas. It has certain therapeutic product development programs, such as CMS101 and CRA102, and CAMI103. In October 2010, the Company launched a wholly owned subsidiary, Advangen International Pty Ltd.

Financial Summary
BRIEF: For the six months ended 31 December 2011, Cellmid Limited's revenues totaled A$111K, up from A$43K. Net loss increased 4% to A$664K. Revenues reflect a presence of gain on foreign exchange, higher income from sale of goods and a significant increase in other income. Higher net loss reflects a significant increase in professional fees, higher employee benefit expenses, an increase in patent costs, a rise in finance costs and higher travel expenses.

Business Address


Level 6, 40 King Street
SYDNEY, NSW 2000
Phone: 61-2-92990311
Fax: 61-2-92992198
http://www.cellmid.com.au

ASX Share Price Information
Current Price 0.015
Current Price Date 21/05/2012
52 Week Hi/Low 0.03 - 0.01
Avg Volume Last ten Days 4.56
ASX Company Sizing
Market Cap 7.17
Revenues 6.13
EBITDA -2.66
Net Income -2.27
Number of Employees -
Enterprise Value 6.13
Research Analyst Forecast
Consensus Recommendation -
Target Price -
LT Growth Rate -
Projected P/E -
Sales -
EPS -
Profit -
DPS -
Share Ratios
EPS -0.00641
RPS 0.00043
BV per Share 0.00513
Cash per Share 0.00401
Cashflow per Share -0.00638
Cashflow per Share 0.00000
Financial Ratios
Gross Margin -706.54170
ROE -92.88651
Price/Sales 47.12320
P/E -
P/Book 2.92232